What is Tesamorelin?
Tesamorelin is a synthetic GHRH analog that is FDA-approved (as Egrifta) for the treatment of HIV-associated lipodystrophy (excess visceral fat). It is the only FDA-approved peptide specifically for visceral fat reduction and has strong clinical evidence for body composition improvement.
Mechanism of Action
Tesamorelin binds to GHRH receptors in the pituitary, stimulating GH release. The elevated GH then drives IGF-1 production, which promotes lipolysis (fat breakdown) specifically in visceral adipose tissue. It has a stabilized structure that gives it a longer half-life than native GHRH.
Tesamorelin Dosing Protocol
2 mg subcutaneous injection daily (FDA-approved dose). Some researchers use 1 mg/day for anti-aging purposes. Inject in the morning or before bed on an empty stomach.
Want a personalized protocol? Tell PepBot your goals, health status, and experience level for a custom Tesamorelin protocol.
Tesamorelin Benefits
Side Effect Profile
Fluid retention, joint pain, carpal tunnel syndrome (GH-related effects). Glucose intolerance at high doses. Generally well-tolerated at standard doses.
Tesamorelin Stacking Guide
Tesamorelin works synergistically with these compounds. Click any to learn more, or ask PepBot to build you a complete stack.
Research & Citations
Frequently Asked Questions about Tesamorelin
Is Tesamorelin better than HGH for fat loss?
Still have questions about Tesamorelin?
PepBot has encyclopedic knowledge of Tesamorelin — dosing, stacking, interactions, latest research, and personalized protocols. Ask anything.